BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 9674872)

  • 1. Predictive factors of tumor response and prognostic factors of survival during lung cancer chemotherapy.
    Ray P; Quantin X; Grenìer J; Pujol JL
    Cancer Detect Prev; 1998; 22(4):293-304. PubMed ID: 9674872
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Markov model and markers of small cell lung cancer: assessing the influence of reversible serum NSE, CYFRA 21-1 and TPS levels on prognosis.
    Boher JM; Pujol JL; Grenier J; Daurès JP
    Br J Cancer; 1999 Mar; 79(9-10):1419-27. PubMed ID: 10188885
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neuroendocrine and cytokeratin serum markers as prognostic determinants of small cell lung cancer.
    Pujol JL; Quantin X; Jacot W; Boher JM; Grenier J; Lamy PJ
    Lung Cancer; 2003 Feb; 39(2):131-8. PubMed ID: 12581564
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ProGRP and NSE in therapy monitoring in patients with small cell lung cancer.
    Wójcik E; Kulpa JK; Sas-Korczyńska B; Korzeniowski S; Jakubowicz J
    Anticancer Res; 2008; 28(5B):3027-33. PubMed ID: 19031951
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cyfra 21-1, neuron specific enolase and prognosis of non-small cell lung cancer: prospective study in 621 patients.
    Pujol JL; Boher JM; Grenier J; Quantin X
    Lung Cancer; 2001; 31(2-3):221-31. PubMed ID: 11165401
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Elevated serum NSE level in locally advanced and metastatic NSCLC predispose to better response to chemotherapy but worse survival].
    Załeska M; Szturmowicz M; Zych J; Roszkowska-Sliz B; Demkow U; Langfort R; Roszkowski-Sliz K
    Pneumonol Alergol Pol; 2010; 78(1):14-20. PubMed ID: 20162514
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of Tc-99m sestamibi, serum neuron-specific enolase and lactate dehydrogenase as predictors of response to chemotherapy in small cell lung cancer.
    Lim SC; Park KO; Kim YC; Na KJ; Song H; Bom HS
    Cancer Biother Radiopharm; 2000 Aug; 15(4):381-6. PubMed ID: 11041023
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Elevated serum levels of TPS and CYFRA 21-1 predict poor prognosis in advanced non-small-cell lung cancer patients treated with gefitinib.
    Chen F; Luo X; Zhang J; Lu Y; Luo R
    Med Oncol; 2010 Sep; 27(3):950-7. PubMed ID: 19830603
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neuron-specific enolase, thymidine kinase, and tissue polypeptide-specific antigen in diagnosis and response to chemotherapy of small-cell lung cancer.
    Abbasciano V; Sartori S; Trevisani L; Nielsen I; Ferrazzi E; Bononi A; Toso S; Crepaldi G; Bianchi MP; Gilli G; Zavagli G
    Cancer Detect Prev; 1999; 23(4):309-15. PubMed ID: 10403902
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correlation of in vitro drug sensitivity testing results with response to chemotherapy and survival: comparison of non-small cell lung cancer and small cell lung cancer.
    Shaw GL; Gazdar AF; Phelps R; Steinberg SM; Linnoila RI; Johnson BE; Oie HK; Russell EK; Ghosh BC; Pass HI; Minna JD; Mulshine JL; Ihde DC
    J Cell Biochem Suppl; 1996; 24():173-85. PubMed ID: 8806100
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumour markers CEA, NSE, SCC, TPA and CYFRA 21.1 in resectable non-small cell lung cancer.
    Foa P; Fornier M; Miceli R; Seregni E; Santambrogio L; Nosotti M; Cataldo I; Sala M; Caldiera S; Bombardieri E
    Anticancer Res; 1999; 19(4C):3613-8. PubMed ID: 10629660
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytokeratins as serum markers in lung cancer: a comparison of CYFRA 21-1 and TPS.
    Pujol JL; Grenier J; Parrat E; Lehmann M; Lafontaine T; Quantin X; Michel FB
    Am J Respir Crit Care Med; 1996 Sep; 154(3 Pt 1):725-33. PubMed ID: 8810612
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic value of serum tumor markers in patients with lung cancer.
    Hatzakis KD; Froudarakis ME; Bouros D; Tzanakis N; Karkavitsas N; Siafakas NM
    Respiration; 2002; 69(1):25-9. PubMed ID: 11844959
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum neuron-specific enolase and lactate dehydrogenase as predictors of response to chemotherapy and survival in non-small cell lung cancer.
    van Zandwijk N; Jassem E; Bonfrer JM; Mooi WJ; van Tinteren H
    Semin Oncol; 1992 Feb; 19(1 Suppl 2):37-43. PubMed ID: 1329221
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cytokeratin-19 fragments, nucleosomes and neuron-specific enolase as early measures of chemotherapy response in non-small cell lung cancer.
    Alm El-Din MA; Farouk G; Nagy H; Abd Elzaher A; Abo El-Magd GH
    Int J Biol Markers; 2012 Jul; 27(2):e139-46. PubMed ID: 22467097
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association between serum biomarkers CEA and LDH and response in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy.
    de Jong C; Deneer VHM; Kelder JC; Ruven H; Egberts TCG; Herder GJM
    Thorac Cancer; 2020 Jul; 11(7):1790-1800. PubMed ID: 32383328
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of the serum markers CEA, NSE, TPS and CYFRA 21.1 in lung cancer.
    Giovanella L; Ceriani L; Bandera M; Beghe B; Roncari G
    Int J Biol Markers; 1995; 10(3):156-60. PubMed ID: 8551058
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Decline in serum carcinoembryonic antigen and cytokeratin 19 fragment during chemotherapy predicts objective response and survival in patients with advanced nonsmall cell lung cancer.
    Ardizzoni A; Cafferata MA; Tiseo M; Filiberti R; Marroni P; Grossi F; Paganuzzi M
    Cancer; 2006 Dec; 107(12):2842-9. PubMed ID: 17103443
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Circulating serum vascular endothelial growth factor is not a prognostic factor of non-small cell lung cancer.
    Chakra M; Pujol JL; Lamy PJ; Bozonnat MC; Quantin X; Jacot W; Daurès JP
    J Thorac Oncol; 2008 Oct; 3(10):1119-26. PubMed ID: 18827607
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The diagnostic and prognostic value of ProGRP in lung cancer.
    Nisman B; Biran H; Ramu N; Heching N; Barak V; Peretz T
    Anticancer Res; 2009 Nov; 29(11):4827-32. PubMed ID: 20032442
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.